These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 9314292)

  • 1. Conceptual basis for advances in the systemic drug therapy of breast cancer.
    Norton L
    Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-2-S11-12. PubMed ID: 9314292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients.
    Zielinski CC; Awada A; Cameron DA; Cufer T; Martin M; Aapro M
    Eur J Cancer; 2008 Feb; 44(3):353-65. PubMed ID: 18191396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/II clinical trial of epirubicin and paclitaxel followed by granulocyte colony-stimulating factor in a 2-week schedule in patients with advanced or metastatic breast cancer.
    Ries F; Duhem C; Kleiber K; Dicato M
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-48-S17-51. PubMed ID: 9374093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-intense paclitaxel, etoposide and cyclophosphamide: a safe and active regimen for tumor cytoreduction and stem cell mobilization in metastatic breast cancer.
    Bilgrami S; Feingold JM; Bona RD; Edwards RL; Khan AM; Rodriguez-Pinero F; Khan IA; Kazierad D; Clive J; Tutschka PJ
    Bone Marrow Transplant; 2000 Jan; 25(2):123-30. PubMed ID: 10673668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The current state of adjuvant therapy for breast cancer: focus on paclitaxel.
    Hudis CA
    Semin Oncol; 1999 Feb; 26(1 Suppl 2):1-5. PubMed ID: 10190778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of neutropenia on delivering planned chemotherapy for solid tumours.
    Khan S; Dhadda A; Fyfe D; Sundar S
    Eur J Cancer Care (Engl); 2008 Jan; 17(1):19-25. PubMed ID: 18181887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer.
    De Placido S; Lauria R; Carlomagno C; Perrone F; De Laurentiis M; Gallo C; Martignetti A; Bellelli T; Limite G; Petrella G; Bianco AR
    Int J Oncol; 1999 Aug; 15(2):339-46. PubMed ID: 10402245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose and schedule as determinants of outcomes in chemotherapy for breast cancer.
    Budman DR
    Semin Oncol; 2004 Dec; 31(6 Suppl 15):3-9. PubMed ID: 15726532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of repetitive cycles of dose-intense carboplatin plus paclitaxel chemotherapy and peripheral blood stem cells in metastatic breast cancer.
    Ford C; Spitzer G; Reilly W; Adkins D
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-81-S17-86. PubMed ID: 9374101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Importance of dose intensity in chemotherapy--lessons from adjuvant chemotherapy for early breast cancer].
    Tamura K
    Rinsho Ketsueki; 2009 Apr; 50(4):276-81. PubMed ID: 19404020
    [No Abstract]   [Full Text] [Related]  

  • 11. Dose-dense chemotherapy for primary breast cancer.
    Kümmel S; Rezai M; Kimmig R; Schmid P
    Curr Opin Obstet Gynecol; 2007 Feb; 19(1):75-81. PubMed ID: 17218856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer.
    Rahman Z; Champlin R; Rondon G; Frye D; Valero V; Mehra R; Hortobagyi G
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-77-S17-80. PubMed ID: 9374100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant breast cancer therapy: current status and future strategies--growth kinetics and the improved drug therapy of breast cancer.
    Norton L
    Semin Oncol; 1999 Feb; 26(1 Suppl 3):1-4. PubMed ID: 10203263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer.
    Elias AD; Richardson P; Avigan D; Ibrahim J; Joyce R; Demetri G; Levine J; Warren D; Arthur T; Reich E; Wheele C; Frei E; Ayash L
    Bone Marrow Transplant; 2001 Feb; 27(3):269-78. PubMed ID: 11277174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
    Edelman MJ; Meyers FJ; Houston J; Lauder I
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weekly epirubicin and paclitaxel with granulocyte colony-stimulating factor support in previously untreated metastatic breast cancer patients: a phase II study.
    Nisticò C; Bria E; Cuppone F; Fornier M; Sperduti I; Carpino A; Pace A; Cognetti F; Terzoli E
    Anticancer Drugs; 2007 Jul; 18(6):687-92. PubMed ID: 17762397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequence-dependent hematological toxicity associated with the 3-hour paclitaxel/cyclophosphamide doublet.
    Kennedy MJ; Zahurak ML; Donehower RC; Noe D; Grochow LB; Sartorius S; Chen TL; Bowling K; Duerr M; Rowinsky EK
    Clin Cancer Res; 1998 Feb; 4(2):349-56. PubMed ID: 9516922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current limits of knowledge in adjuvant and neoadjuvant endocrine therapy of breast cancer: the need for more clinical research.
    Hayward RL; Dixon JM
    Surg Oncol; 2003 Dec; 12(4):289-304. PubMed ID: 14998569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Studies with high-dose chemotherapy and subsequent autologous stem cell transplantation in breast carcinoma].
    Nitz U; Adomeit A; Mohrmann S; Fossari A; Frick M
    Praxis (Bern 1994); 1998 Apr; 87(17):578-83. PubMed ID: 9623324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does paclitaxel decrease the interstitial fluid pressure and improve oxygenation in breast cancer in a schedule-dependent fashion?
    Altundag K; Altundag O; Turen S
    Med Hypotheses; 2005; 65(5):1002-3. PubMed ID: 15946804
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.